Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity

被引:44
作者
Blunt, Christopher E. [1 ]
Torcuk, Canan [2 ]
Liu, Yang [1 ]
Lewis, William [1 ]
Siegel, David [2 ]
Ross, David [2 ]
Moody, Christopher J. [1 ]
机构
[1] Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England
[2] Univ Colorado, Dept Pharmaceut Sci, Aurora, CO 80045 USA
关键词
Diels-Alder reaction; oxidoreductases; quinones; redox chemistry; sulfur; nitrogen heterocycles; 2,3-DIOXYGENASE (IDO). SYNTHESIS; INDOLEAMINE 2,3-DIOXYGENASE; NAD(P)H-QUINONE OXIDOREDUCTASE-1; SPONTANEOUS HYPERTENSION; ACTIVATION; INHIBITORS; CANCER; PURIFICATION; ANTIBIOTICS; SUPPRESSION;
D O I
10.1002/anie.201503323
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Natural quinones, often linked with cellular oxidation processes, exhibit pronounced biological activity. In particular, the structurally unique isothiazolonaphthoquinone aulosirazole, isolated from blue-green alga, possesses selective antitumor cytotoxicity, although its mechanism of action is unknown. The first synthesis of aulosirazole uses a route centered upon a late-stage regioselective Diels-Alder reaction. The structurally related natural product pronqodineA, an inhibitor of prostaglandin release, and analogues thereof, were also prepared for comparison. Biological evaluation of the compounds identified one potential target as the immunoregulatory enzyme indoleamine-2,3-dioxygenase (IDO). The isothiazoloquinones are also efficient substrates for the human quinone reductase NQO1, and undergo intracellular NQO1-dependent redox cycling resulting in the generation of reactive oxygen species, and at lower doses have the potential to alter the ratio of intracellular oxidized to reduced pyridine nucleotides.
引用
收藏
页码:8740 / 8745
页数:6
相关论文
共 51 条
[1]  
[Anonymous], 2014, ASCO M
[2]   Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenase [J].
Austin, CJD ;
Mizdrak, J ;
Matin, A ;
Sirijovski, N ;
Kosim-Satyaputra, P ;
Willows, RD ;
Roberts, TH ;
Truscott, RJW ;
Polekhina, G ;
Parker, MW ;
Jamie, JF .
PROTEIN EXPRESSION AND PURIFICATION, 2004, 37 (02) :392-398
[3]   REACTIONS OF KETEN ACETALS .1. SIMPLE SYNTHESIS OF SOME NATURALLY OCCURRING ANTHRAQUINONES [J].
BANVILLE, J ;
GRANDMAI.JL ;
LANG, G ;
BRASSARD, P .
CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE, 1974, 52 (01) :80-87
[4]   REGIOSPECIFIC ADDITION OF MONOOXYGENATED DIENES TO HALO QUINONES [J].
BOISVERT, L ;
BRASSARD, P .
JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (17) :4052-4059
[5]   POLYCYCLIC HYDROXYQUINONES .13. A NOVEL SYNTHESIS OF ISLANDICIN AND DIGITOPURPONE [J].
CANO, P ;
ECHAVARREN, A ;
PRADOS, P ;
FARINA, F .
JOURNAL OF ORGANIC CHEMISTRY, 1983, 48 (26) :5373-5376
[6]   Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and biological evaluation [J].
Carvalho, Catarina ;
Siegel, David ;
Inman, Martyn ;
Xiong, Rui ;
Ross, David ;
Moody, Christopher J. .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2014, 12 (17) :2663-2674
[7]   Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:Quinone oxidoreductase 1 (NQO1) activity [J].
Colucci, Marie A. ;
Reigan, Philip ;
Siegel, David ;
Chilloux, Aurelie ;
Ross, David ;
Moody, Christopher J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (23) :5780-5789
[8]  
COREY EJ, 1975, TETRAHEDRON LETT, P2389
[9]   Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H: Quinone oxidoreductase-directed antitumor quinones: Evaluation of the activity of RH1 [J].
Dehn, DL ;
Winski, SL ;
Ross, D .
CLINICAL CANCER RESEARCH, 2004, 10 (09) :3147-3155
[10]   5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl] indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo [J].
Dehn, Donna L. ;
Siegel, David ;
Zafar, Khan Shoeb ;
Reigan, Philip ;
Swann, Elizabeth ;
Moody, Christopher J. ;
Ross, David .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (07) :1702-1709